Opinion

Video

Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how health care professionals use standardized antibody-drug conjugate (ADC) pathways to guide dosing, adverse effect (AE) management, and transitions. Protocols ensure monitoring, toxicity mitigation, and seamless shifts between therapies for optimal care.

Video content above has been prompted by the following:

  • How does your institution incorporate treatment pathways or workflows to guide decision-making, dosing, AE management/monitoring, and patient transitions between different ADCs?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
3 experts are featured in this series.
Related Content
A middle-aged breast cancer woman with clothing around her head effected from chemo therapy sitting on wheel chair and hold hand of her daughter with hope and trust in love. | Image Credit: Bangkok Click Studio | stock.adobe.com
September 4th 2025

Dual Inhibition of KAT6A/B and Menin: A Promising Strategy for ER+ Breast Cancer

Danielle Valletti, Assistant Editor
pharmacy focus oncology edition
September 4th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Breast cancer and SERDs -- Image credit: Phongsakorn | stock.adobe.com
September 4th 2025

Oral SERDs in Breast Cancer: Imulnestrant and Elacestrant

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
September 4th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Ambulatory chemotherapy | Image Credit: RFBSIP | stock.adobe.com
September 4th 2025

Limited Benefit of Adjuvant Chemotherapy in Older Women With HR-Positive, HER2-Negative Breast Cancer

Danielle Valletti, Assistant Editor
Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes
September 4th 2025

Selection Considerations for Abemaciclib Versus Ribociclib in Early HR+/HER2- Breast Cancer: Efficacy, Safety, and Long-Term Outcomes

Benjamin Gibson, PharmD, PAHM
© 2025 MJH Life Sciences

All rights reserved.